Search Results 151-160 of 17322 for egfr

1. Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer - Mayo Clinic

   - BRAF mutation mutant allele frequency (MAF) > 0.5%. - EGFR mutation (MAF > 0.5%). Note: EGFR S492R, K467, and R451C mutations are not an exclusion ...

2. A Study To Assess Disease Activity And Adverse Events Of Intravenous (IV) Telisotuzumab Vedotin Compared To IV Docetaxel In Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - Mayo Clinic

   - A known epidermal growth factor receptor (EGFR) activating mutation status. - Actionable alterations in genes other than EGFR . - Measurable disease per ...

3. An Open-label, Phase 2 Basket Study of Neratinib in Patients with Solid Tumors with Somatic Activating HER Mutations - Mayo Clinic

   ... EGFR gene-amplified solid tumors. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments ...

4. A Study of Artificial Intelligence for Detection of High Potassium Levels in the Emergency Department Using Multilead ECG Devices - Mayo Clinic

   ... eGFR is not an exclusion criteria. KardiaK was trained and tested on ECGs from patients regardless of eGFR level, so we have no reason to believe the ...

5. A Study To Evaluate The Effectiveness And Safety Of Exenatide SR For Diabetes Prevention Following Kidney Transplantation - Mayo Clinic

   Decrease in renal function to eGFR to < 30 ml/min after study initiation. Decrease in eGFR by 50% on the 2 consecutive measurements without otherwise ...

6. Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) - Mayo Clinic

   ... (EGFR) monoclonal antibody. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or ...

7. A Study To Evaluate The Efficacy And Safety Of GDC-8264 In Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) And Major Adverse Kidney Events (MAKE) - Mayo Clinic

   ... eGFR < 60 milliliters/ minutes/ 1.73 meter square (ml/min/1.73 m^2) within the last 6 months, diabetes (type 1 or type 2) requiring at least one oral ...

8. A Study to Evaluate the Addition of Immunotherapy into Adjuvant Therapy for Non-small Cell Lung Cancer - Mayo Clinic

   Participation eligibility · Individuals, ≥ 18 years of age. · Previously registered to A151216. · Central and/or local testing of EGFR with no EGFR exon 19 ...

9. Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

   Male and female subjects with eGFR between 25-65 mL/min/1.73m2 (if aged 18 to55) or eGFR between 25-44 mL/min/1.73m2 (if aged 56 to <66); Tolvaptan naïve ...

10. A Study Of Cemdisiran In Adults With Immunoglobulin A Nephropathy (IgAN) - Mayo Clinic

    Has poor kidney function with estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m^2. Has known human immunodeficiency virus (HIV) infection ...